PL2931720T3 - Stała dyspersja o ulepszonej rozpuszczalności, zawierająca pochodną tetrazolu jako składnik czynny - Google Patents

Stała dyspersja o ulepszonej rozpuszczalności, zawierająca pochodną tetrazolu jako składnik czynny

Info

Publication number
PL2931720T3
PL2931720T3 PL13863463T PL13863463T PL2931720T3 PL 2931720 T3 PL2931720 T3 PL 2931720T3 PL 13863463 T PL13863463 T PL 13863463T PL 13863463 T PL13863463 T PL 13863463T PL 2931720 T3 PL2931720 T3 PL 2931720T3
Authority
PL
Poland
Prior art keywords
active ingredient
solid dispersion
improved solubility
tetrazole derivative
tetrazole
Prior art date
Application number
PL13863463T
Other languages
English (en)
Inventor
Yong Il Kim
Jun Young Choi
Young Keun Choi
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Publication of PL2931720T3 publication Critical patent/PL2931720T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13863463T 2012-12-13 2013-12-12 Stała dyspersja o ulepszonej rozpuszczalności, zawierająca pochodną tetrazolu jako składnik czynny PL2931720T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020120145603A KR101986683B1 (ko) 2012-12-13 2012-12-13 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
PCT/KR2013/011545 WO2014092489A1 (en) 2012-12-13 2013-12-12 Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
EP13863463.9A EP2931720B1 (en) 2012-12-13 2013-12-12 Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient

Publications (1)

Publication Number Publication Date
PL2931720T3 true PL2931720T3 (pl) 2019-09-30

Family

ID=50934681

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13863463T PL2931720T3 (pl) 2012-12-13 2013-12-12 Stała dyspersja o ulepszonej rozpuszczalności, zawierająca pochodną tetrazolu jako składnik czynny

Country Status (38)

Country Link
US (1) US9283218B2 (pl)
EP (1) EP2931720B1 (pl)
JP (1) JP6355645B2 (pl)
KR (1) KR101986683B1 (pl)
CN (1) CN104870443B (pl)
AR (2) AR093706A1 (pl)
AU (1) AU2013360544B2 (pl)
BR (1) BR112015013905A2 (pl)
CA (1) CA2892376C (pl)
CL (1) CL2015001551A1 (pl)
CR (1) CR20150361A (pl)
DK (1) DK2931720T3 (pl)
DO (1) DOP2015000128A (pl)
EC (1) ECSP15029808A (pl)
ES (1) ES2731806T3 (pl)
GT (1) GT201500123A (pl)
HU (1) HUE044659T2 (pl)
IL (1) IL239327A (pl)
JO (1) JO3534B1 (pl)
LT (1) LT2931720T (pl)
MX (1) MX363644B (pl)
MY (1) MY174746A (pl)
NI (1) NI201500073A (pl)
NZ (1) NZ709071A (pl)
PE (1) PE20151066A1 (pl)
PH (1) PH12015501312B1 (pl)
PL (1) PL2931720T3 (pl)
PT (1) PT2931720T (pl)
PY (1) PY1358434A (pl)
RU (1) RU2662819C2 (pl)
SA (1) SA515360535B1 (pl)
SG (1) SG11201504067SA (pl)
SI (1) SI2931720T1 (pl)
TR (1) TR201908746T4 (pl)
TW (1) TWI652073B (pl)
UY (1) UY35186A (pl)
WO (1) WO2014092489A1 (pl)
ZA (1) ZA201503795B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102044223B1 (ko) * 2016-09-12 2019-11-13 성균관대학교산학협력단 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법
JP7561629B2 (ja) 2018-03-07 2024-10-04 シアン チェン アンドリュー 不溶性薬物用の水性製剤
CZ2018188A3 (cs) * 2018-04-18 2019-10-30 Zentiva, K.S. Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek
AU2019395284B2 (en) * 2018-12-14 2025-07-17 Health Hope Pharma Hk Limited Therapeutic combinations of orally administered irinotecan and a P-gp inhibitor for the treatment of cancer
EP3893867A1 (en) 2018-12-14 2021-10-20 Athenex HK Innovative Limited Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer
US12404267B2 (en) * 2019-02-14 2025-09-02 Assia Chemical Industries Ltd. Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
US20230278990A1 (en) * 2020-07-10 2023-09-07 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
JP7823036B2 (ja) 2020-10-07 2026-03-03 ヘルス ホープ ファーマ エイチケー リミテッド アセトアミド-フェニルテトラゾール誘導体およびその使用方法
JP2023548384A (ja) * 2020-10-30 2023-11-16 アテネックス アールアンドディ エルエルシー Hm30181メシル酸塩の多形

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP2000309588A (ja) * 1999-04-28 2000-11-07 Taisho Pharmaceut Co Ltd 固体分散体
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
KR100557093B1 (ko) * 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR100572411B1 (ko) 2003-10-23 2006-04-18 한미약품 주식회사 열역학적으로 안정한 무정형 토라세미드 고체분산체와이를 포함하는 약학 조성물 및 이의 제조 방법
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
ZA200801893B (en) * 2005-08-29 2009-08-26 Sanofi Aventis Us Llc Amorphous solid dispersions of 7-chloro-N,N, 5-Trimethyl-4-Oxo-3-phenyl-3, 5,-dihydro-4H-pyridazino [4,5-B] indole-1-acetamide
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
KR20110132116A (ko) * 2010-06-01 2011-12-07 (주)국전약품 라록시펜 염산염을 포함하는 고체분산체, 이의 제조방법, 및 이를 포함하는 경구용 제제
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase

Also Published As

Publication number Publication date
LT2931720T (lt) 2019-07-10
HK1212330A1 (en) 2016-06-10
BR112015013905A2 (pt) 2017-07-11
NZ709071A (en) 2019-08-30
PE20151066A1 (es) 2015-08-11
MX363644B (es) 2019-03-29
SA515360535B1 (ar) 2017-07-17
ZA201503795B (en) 2016-08-31
JP6355645B2 (ja) 2018-07-11
NI201500073A (es) 2016-01-06
ECSP15029808A (es) 2016-01-29
MY174746A (en) 2020-05-13
AU2013360544A1 (en) 2015-07-09
UY35186A (es) 2014-07-31
CA2892376A1 (en) 2014-06-19
PT2931720T (pt) 2019-06-25
SI2931720T1 (sl) 2019-08-30
GT201500123A (es) 2018-10-08
SG11201504067SA (en) 2015-06-29
US20150272943A1 (en) 2015-10-01
CL2015001551A1 (es) 2015-09-25
JO3534B1 (ar) 2020-07-05
WO2014092489A1 (en) 2014-06-19
PY1358434A (es) 2017-01-02
IL239327A0 (en) 2015-07-30
TR201908746T4 (tr) 2019-07-22
RU2662819C2 (ru) 2018-07-31
CN104870443B (zh) 2018-09-14
MX2015006416A (es) 2015-08-14
PH12015501312A1 (en) 2015-08-24
AR123783A2 (es) 2023-01-11
EP2931720A4 (en) 2016-06-29
PH12015501312B1 (en) 2015-08-24
TW201429507A (zh) 2014-08-01
CA2892376C (en) 2020-10-27
AR093706A1 (es) 2015-06-17
TWI652073B (zh) 2019-03-01
HUE044659T2 (hu) 2019-11-28
JP2016507489A (ja) 2016-03-10
AU2013360544B2 (en) 2017-05-11
IL239327A (en) 2017-11-30
RU2015128002A (ru) 2017-01-16
US9283218B2 (en) 2016-03-15
KR101986683B1 (ko) 2019-06-10
DK2931720T3 (da) 2019-07-08
CN104870443A (zh) 2015-08-26
DOP2015000128A (es) 2015-09-30
ES2731806T3 (es) 2019-11-19
KR20140076979A (ko) 2014-06-23
CR20150361A (es) 2015-08-21
EP2931720B1 (en) 2019-04-24
EP2931720A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
DK3077374T3 (da) Pyrrolidinoner som herbicider
PL2931720T3 (pl) Stała dyspersja o ulepszonej rozpuszczalności, zawierająca pochodną tetrazolu jako składnik czynny
SMT201700065B (it) Derivato piridonico
EP3517152C0 (en) DRUG ADMINISTRATION CONNECTORS
CL2014002700A1 (es) Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo
EP2762476A4 (en) 1,2,4-triazine-6-carboxamide derivative
ZA201504197B (en) N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxamides derivatives
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
DK2938194T3 (da) N-(substituerede)-5-fluor-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidin-1 (2h)-carboxylatderivater
BR112014027814A2 (pt) agentes sinérgicos antimicrobianos.
EP2828395A4 (en) CONJUGATES OF BORONIC ACID OF OLIGONUCLEOTIDE ANALOGUES
CL2014003459A1 (es) Compuestos fungicidas heterocíclicos.
BR112015004938A2 (pt) combinações de compostos ativos
CL2014003283A1 (es) Formulación farmacéutica.
PL2897984T3 (pl) Wodna kompozycja emulsyjna nadtlenku organicznego
BR112015004825A2 (pt) composição microbicida aquosa.
CO6920301A2 (es) Derivados insecticidas de 2-metoxibenzamida
ZA201308371B (en) Sustained release pheromone formulation
GB201320585D0 (en) Insecticidal compounds based on arylthiosulfonamide derivatives
BR112015000557A2 (pt) rebobinadeira.
DK2672817T4 (da) Forbedrede insekticide formuleringer
CO7020920A2 (es) Derivado de fenilazol sustituido
DK2851075T3 (da) Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
BR112015011494A2 (pt) combinações de compostos ativos
ZA201306135B (en) Active composition for a decoy which radiates spectrally on burnup of the active composition,comprising an additive